Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. RESEARCH DESIGN AND METHODS: A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic. RESULTS: In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%). CONCLUSIONS: Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (162,163), which may be limited to those with diabetes risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“To assess heterogeneity across studies, we used the Cochran Q statistic based on the pooled RR by Mantel-Haenszel and measured inconsistency (I(2); the percentage of total variance across studies attributable to heterogeneity rather than chance) of treatment effects across trials (9).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The summary RR and its 95% CI were estimated using the DerSimonian and Laird method for random effects (8).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Subsequent statin trials did not confirm this protective effect, and in the recent JUPITER a small but significant increase in physician-reported diabetes was reported among statin users compared with those taking placebo, although in the absence of any effect on glucose levels (6).”
ResultSelf-citationSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“A few studies have suggested that statin use may result in an increase in A1C levels (2,17), although these effects have been quite small.”
BackgroundRosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · cited 1×
“(1) reported an inverse association between pravastatin use and diabetes incidence in the WOSCOPS (RR 0.”
Background
Research works printed but not linked: 1
- Sabatine, 2004, High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract), Circulation, 110, S834
Cited by
Items 301–400 of 439
How Low an LDL-C Should We Go With Statin Therapy?
Kostis, W. J. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0388-7 · Cited by 8
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 13
Beneficial Effect of Atorvastatin on Renal Function in Patients with Type 2 Diabetes
Tanaka, M. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900440 · Cited by 7
Dautović, E., Rustemović-Čorbić, M., Srabović, N., Softič, A., Smajlović, A., Husejnović, M. Š., Hatkić, A., & Halilčević, D. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.07.002 · Cited by 10
Current and Emerging Therapies in Hypercholesterolemia: Focus on Colesevelam
Ijioma, N., & Robinson, J. G. (2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s1573 · Cited by 7
Intensive statin therapy for Indians: Part-I. Benefits.
Enas, E. A., Pazhoor, H. C., Kuruvila, A. T., & Vijayaraghavan, K. (2011) · PubMed · Cited by 8
Kim, J., Kim, M., Kim, M.-J., You, Y., Song, Y., & Lee, B. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155795 · Cited by 6
Counterpoint: The evidence does not support universal screening and treatment in children
Belamarich, P. F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.07.001 · Cited by 6
“09 noted in a large meta-analysis.(27,29) The Food and Drug Administration recognized the increased risk of diabetes in 2012.”
BackgroundYamazaki, K., Takahashi, Y., Teduka, K., Nakayama, T., Nishida, Y., & Asai, S. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0314-x · Cited by 8
Engeda, J. C., Lhachimi, S. K., Rosamond, W. D., Lund, J. L., Keyserling, T. C., Safford, M. M., Colantonio, L. D., Muntner, P., & Avery, C. L. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003280 · Cited by 6
Петровна, З. А., Gemoets, D. E., Kaminsky, L. S., & Gosmanov, A. R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002554 · Cited by 6
McFadden, E. C., Stevens, R., Glasziou, P., & Perera, R. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.11.004 · Cited by 9
“The extensive literature on non-cardiovascular effects of statins has recently been reviewed (Desai et al., 2014): the best documented harms include an increased risk of diabetes, for example (Rajpathak et al., 2009; Sattar et al., 2010).”
BackgroundForbidden Fruit: On the Analysis of Recurrent Events in Randomized Clinical Trials
Diamond, G. A., & Kaul, S. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.310 · Cited by 6
What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed, M. H. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32833dadc3 · Cited by 6
Pharmacogenomics in the Development and Characterization of Atheroprotective Drugs
Valanti, E., Tsompanidis, A., & Sanoudou, D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_11 · Cited by 6
Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs
Zhang, X., Gu, Y. H., Deng, H., Xu, Z. Q., Zhong, Z., Lyu, X. J., Jin, H. M., & Yang, X. H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.691336 · Cited by 6
Balaji, J. N., Prakash, S., Joshi, A., & Surapaneni, K. M. (2022) · Clinics and Practice · doi:10.3390/clinpract12040060 · Cited by 7
“On analyzing the glycated hemoglobin, statin users were found to have elevated HbA1C levels that were particularly significant with atorvastatin compared withpravastatin [38,39].”
BackgroundRoss, S. M. (2016) · Holistic Nursing Practice · doi:10.1097/hnp.0000000000000192 · Cited by 7
Grice, B. A., & Elmendorf, J. S. (2017) · US Endocrinology · doi:10.17925/use.2017.13.02.63 · Cited by 6
Estimating the effect of lipid‐lowering agents on novel subtypes of adult‐onset diabetes
Ye, J., Guo, K., Li, J., Li, X., Zhou, Z., & Yang, L. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3793 · Cited by 5
Drug therapy for the prevention of type 2 diabetes – is there a medical rationale?
Hanefeld, M., & Schäper, F. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411403987 · Cited by 5
Statin use and incident type 2 diabetes mellitus in women after menopause
Anelli, V., Armeni, E., Paschou, S. Α., & Lambrinoudaki, I. V. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.107914 · Cited by 5
Statins: An Update on Clinical Issues and Selected Adverse Effects
Gulum, A. H., & Hume, A. L. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.09.004 · Cited by 5
Implications of high-dose statin link with incident diabetes
Davidson, M. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.118 · Cited by 5
Shaya, G. E., Juraschek, S. P., Feldman, D. I., Brawner, C. A., Ehrman, J. K., Keteyian, S. J., Al-Mallah, M. H., & Blaha, M. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.048 · Cited by 5
Statin and the risk of new-onset diabetes mellitus
Kim, S. (2017) · Journal of Korean Medical Association · doi:10.5124/jkma.2017.60.11.901 · Cited by 5
Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
Parson (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s8376 · Cited by 5
“This finding has been previously reported 23,24 and was clinically insignificant in this study.”
The Influence of Statins on Glucose Tolerance and Incipient Diabetes
O’Keefe, J. H., DiNicolantonio, J. J., Lavie, C. J., & Bell, D. S. H. (2014) · US Endocrinology · doi:10.17925/use.2014.10.01.68 · Cited by 6
Cho, K., Bahuguna, A., Kim, J.-E., Lee, S. H., Lee, Y., Jeon, C., Baek, S. H., & Djayanti, K. (2026) · Pharmaceuticals · doi:10.3390/ph19020237 · Cited by 5
“Growing evidence affirms a possible connection between statin use and a greater risk of type 2 diabetes [12–14].”
Riesgo de diabetes mellitus tipo 2 asociado al uso de estatinas: evidencias y posibles mecanismos
Suazo, J., & Rigotti, A. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014000200011 · Cited by 7
Barrow, B. M., Wander, P. L., & Zraika, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-25-0048 · Cited by 5
Reiner, Ž. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0121 · Cited by 5
“diabetes per 1,000 person-years of statin use [24–26].”
BackgroundImpact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
Rikhi, R. R., & Shapiro, M. D. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02141-3 · Cited by 7
“Focusing on the initial analysis of 5 statin tri - als, the meta-analysis by Rajpathak et al. illustrates a small increase in new-onset diabetes from statin therapy [16].”
Statins and diabetes mellitus: price of collaboration
Александров, А. А., Ядрихинская, М. Н., Kukharenko, S. S., & Shatskaya, O. A. (2012) · Diabetes Mellitus · doi:10.14341/2072-0351-5522 · Cited by 4
“Схема отбора анализированных статей [16] 568 статей по данным MEDLINE, Cochrane и Science 526 исключены из-за названия и краткого изложения дизайна, состава популяции или интересующих исходов лечения”
InfluentialOstrowska, M., Adamski, P., Koziński, M., Navarese, E. P., & Kubica, J. (2016) · Medical Research Journal · doi:10.5603/fmc.2015.0009 · Cited by 4
“23 for new-onset DM in statin-treated patients as compared with the placebo/no treatment group [26].”
Cerebrovascular pathology and metabolic syndrome
Tanashyan, M. М. (2019) · doi:10.33901/978-5-6041430-2-5-2019-1-370 · Cited by 4
Management of Cardiovascular Disease in Women
Mieszczanska, H. Z., & Velarde, G. P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5517-1 · Cited by 6
Statins are Contraindicant to Diabetics - Urgent Proposal
Okuyama, H., Hamazaki, T., Ogushi, Y., Hama, R., Uchino, H., Watanabe, H. A., & Hashimoto, M. (2013) · Journal of Lipid Nutrition · doi:10.4010/jln.22.173 · Cited by 2
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Deng, B., Li, S., You, R., & Fu, Z. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2418325 · Cited by 3
“Our findings corroborate and extend previous meta-analyses that have associated statin therapy with increased diabetes risk [34,35].”
The problem of safety of lipid-lowering therapy
Zykov, M. V. (2019) · Kardiologiia · doi:10.18087/cardio.2505 · Cited by 4
Adding Ezetimibe to Statin Treatment: is LDL-C Lowering the Only benefit?
Kostapanos, M. S., Mikhailidis, D. P., & Elisaf, M. (2012) · Future Cardiology · doi:10.2217/fca.12.64 · Cited by 3
“Meta-analyses have demonstrated that statins may increase the risk of new-onset diabetes [39,40].”
BackgroundTHE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW
Napalkov, D. A. (2014) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2014-10-3-334-338 · Cited by 4
Inasu, S. T., & Kumudavalli, M. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i4.4195 · Cited by 4
KAMIR-NIH Investigators, Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., et al. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00476-z · Cited by 4
Genetic considerations in the treatment of familial hypercholesterolemia
Moyer, A. M., & Baudhuin, L. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.33 · Cited by 4
Devendra, G. P., & Krasuski, R. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e4f13 · Cited by 3
Gonçalves, R. L. S., Wang, Z. B., Inouye, K., Lee, G. Y., Fu, X., Saksi, J., Rosique, C., Parlakgül, G., Arruda, A. P., Hui, S. T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.21.528863 · Cited by 3
“Diabetes Mellitus 2 (15%) Arterial hypertension 4 (31%) Dyslipidemia 5 (38%) BMI (Kg/m2) 32 (28-36) ASAT (U/L) 40 (22-52) ALAT (U/L) 46 (23-65)”
Estatinas y Riesgo de Diabetes
Bastías, E., Victoria Novik, A., & Alejandro Ceriani, B. (2012) · Revista chilena de cardiología · doi:10.4067/s0718-85602012000300007 · Cited by 2
Nalini, R., Ramya, J. E., & Karthick, R. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_943_20 · Cited by 2
Kim, T. J., Lee, J. S., Yoon, J. S., Oh, M. S., Kim, J., Park, S.-H., Yu, K., Lee, B., Ko, S., & Yoon, B. (2024) · Cerebrovascular Diseases · doi:10.1159/000538485 · Cited by 5
“Although statin therapy is bene fi cial for reducing cardiovascular events, it is associated with an increased risk of new-onset diabetes mellitus (NODM) [7 – 10].”
Cheng, W.-Y., Chang, L.-H., & Chen, H.-S. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001114 · Cited by 3
Clinical Trials and Outcomes in Anti-inflammatory Therapies
Shukla, S. P., Kumar, V., Singh, S., Dwivedi, A., & Tripathi, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-0157-5_12 · Cited by 2
Kamiya, K., Takei, M., Nagai, T., Miyoshi, T., Ito, H., Fukumoto, Y., Obara, H., Kakuma, T., Sakuma, I., Daida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64304 · Cited by 2
Role of Statins in PCOS Management
Ortega, I., & Dulęba, A. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_11 · Cited by 3
Polycystic Ovary Syndrome: Update on Treatment Options and Treatment Considerations for the Future
Farrell-Turner, K. A. (2011) · Clinical Medicine Insights Women s Health · doi:10.4137/cmwh.s6715 · Cited by 3
Pharmacological lipid lowering for prevention of cardiovascular disease in older adults
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Clinical Practice · doi:10.2217/cpr.13.83 · Cited by 2
Statins and Incident Diabetes: Can Risk Outweigh Benefit?
Florido, R., Elander, A. G., Blumenthal, R. S., & Martin, S. S. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0444-7 · Cited by 2
Rajpathak, S. N. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.2011.100198 · Cited by 2
Self-citationShimoyama, S. (2015) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000185 · Cited by 3
“First, the diagnostic criteria of NODM were different between studies, with some including an initiation of pharmacotherapy and some including personal or a physician report [12-14].”
BackgroundToxicity to the Insulin-Secreting β-Cell
Long, N. E. D., & Holloway, A. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95676-9 · Cited by 3
Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism
Arkhipov, V. V., Gorodetskaya, G. I., Демидова, О. А., Alexandrova, T. V., & Alexandrov, A. A. (2019) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2019-7-4-163-175 · Cited by 2
Pathogenetic mechanisms of statin dysglycemia and risk of new-onset diabetes
Pappa, M. B., Tsimihodimos, V., & Alaveras, A. (2021) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1018 · Cited by 2
Gari, M., Kumar, A., & Majhee, L. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20172742 · Cited by 2
Do statins adversely affect the HbA1c of diabetic patients?
Son, W. D., & Teng, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 3
Bilous, F. R., & Donnelly, R. (2010) · Wiley eBooks · doi:10.1002/9781444391374.ch18 · Cited by 2
Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study
Chen, Z., Triatin, R. D., Luo, L., Snieder, H., Schmidt, A. F., Ditmarsch, M., Kastelein, J. J. P., Dullaart, R. P. F., Kuivenhoven, J. A., & Thio, C. H. L. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03209-w · Cited by 1
“Over the past decade, however, convincing evidence has accumulated that statins, concomitant with reducing low-density lipoprotein cholesterol (LDL-C) levels, perturb glycemic con-trol, thereby increasing the risk of type 2 diabetes (T2D) [4–9].”
Cho, K., Jeon, C., Bahuguna, A., Kim, J.-E., Lee, S. H., Lee, Y., & Baek, S. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177687 · Cited by 2
“Studies documented the adverse effect of statins (including Ator) on type 2 diabetes [17–19].”
Place des statines chez le sujet âgé
Hammami, R., Jdidi, J., Triki, F., Hammami, B., Abid, L., Ksouda, K., Hammami, S., Abid, D., Hentati, M., & Kammoun, S. (2015) · Therapies · doi:10.2515/therapie/2015057 · Cited by 1
Nicot, P., Guerbaaï, R.-A., & Ennezat, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.093 · Cited by 1
Simonyi, G. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29732 · Cited by 1
Medications affecting glycemic control
Korayem, G. B. (2017) · Integrative Clinical Medicine · doi:10.15761/icm.1000103 · Cited by 2
“Data supporting this statement showed a 5-25% increased risk of NODM or DM treatment in patients receiving statin [59,60].”
BackgroundStatin Therapy in Patients with Type 2 Diabetes Mellitus in Hungary
Márk, L., Reiber, I., Paragh, G., Karádi, I., Pados, G., Kiss, Z., & Jermendy, G. (2015) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2015/22424 · Cited by 1
millan, J. M., Ascaso, J. F., Barrios, V., Cases, A., Serrano, A., Pascual, V., Pedro‐Botet, J., & Pintó, X. (2017) · Journal of Diabetes Research and Therapy · doi:10.16966/2380-5544.128 · Cited by 1
“Once the studies with rosuvastatin are included, the increase in globally considered risk rose to 13% [5], although the inclusion of studies with pravastatin concealed this effect, since the WOSCOPS study with this statin had shown a favourable effect on diabetogenic risk [6].”
Statin Safety: What Every Health Care Provider Needs to Know
Hashi, S., Sathiyakumar, V., Byrne, K., Elshazly, M. B., Jones, S. R., & Martin, S. S. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0565-x · Cited by 1
Hashiguchi, M., Maruyama, J., Shimizu, M., Takahashi, D., & Shiga, T. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.444 · Cited by 1
“(3) The starting date of concomitant medication taken was unknown, but the ending date was known, and its administration continued from before the start of statin administration.”
BackgroundMethodStatins and diabetes mellitus: risks and benefits
Drapkina, O. M., Корнеева, О. Н., & Sheptulina, A. F. (2012) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2012-6-85-90 · Cited by 3
Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
Мазеркина, И. А., Букатина, Т. М., & Aleksandrova, T. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-292-302 · Cited by 1
Sridevi, G., Saravanan, R. R., Gunasekaran, S., & Suresh, M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139656 · Cited by 1
Park, J. H., Lim, K.-T., Lee, J., Gil, Y. J., & Sung, J. (2024) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.24.671 · Cited by 3
South African dyslipidaemia guideline consensus statement
Klug, E., Raal, F. J., Marais, A., Taskinen, M., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2012) · SA Heart · doi:10.24170/9-2-1855 · Cited by 1
Garmendia, F., Pando, R., Ronceros, G., & Muro, P. L. (2019) · Diagnóstico · doi:10.33734/diagnostico.v57i3.179 · Cited by 1
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.015 · Cited by 4
Curiaki, G., Gonzáléz, A. D., Cabrera, M. A. S., Guidoni, C. M., & Girotto, E. (2020) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v49n1.85168 · Cited by 1
“4 Although statins are effective agents for the treatment of dyslipidemia [5], studies have indicated that their use can be associated with an increased risk of developing type 2 diabetes mellitus (DM) [9-11].”
BackgroundDiabetes Caused by Statin Use: A Review
Zulfiana, R., Medina, F., & Suharjono, S. (2020) · Journal of Islamic Pharmacy · doi:10.18860/jip.v5i1.8652 · Cited by 1
Poorhosseini, H., Tavolinejad, H., Aminorroaya, A., Soleimani, H., Aasham, O., Jalali, A., Mohammadi, A., Beigi, S. S., Sadeghian, S., Bagheri, J., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107713 · Cited by 2
Chavez, J. (2018) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro) · Cited by 1
Schwartz, R. G. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9295-2 · Cited by 1
Hackett, R. A. (2016) · UCL Discovery (University College London) · Cited by 2
Shen, X., Ma, S., Vemuri, P., Castro, M. R., Caraballo, P. J., & Simon, G. (2021) · Research Square · doi:10.21203/rs.3.rs-486814/v1 · Cited by 1
Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL
Schwarz, M., & Kim, J. B. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch8
Sánchez, I. O. (2014) · BURJC Digital (King Juan Carlos University)
Masuo, K. (2015) · InTech eBooks · doi:10.5772/59862 · Cited by 2
Armando Pérez, M., Aure, G., & Ruíz-Contreras, J. (2012) · Revista Venezolana de Endocrinología y Metabolismo · Cited by 7
Chan, D. C., & Watts, G. F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.019
Statins induce hyperglycaemia of uncertain importance
Montori, V. M., & Brito, J. P. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-101030
How Low to Go for Primary Prevention?
Robinson, J. G. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0103-y
The emerging role of HDL in glucose
Rye, K., Duffy, S. J., Barter, P. J., & Kingwell, B. A. (2012)
Metadata
- Authors
- Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rajpathak, Swapnil N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-01
- Volume
- 32
- Issue
- 10
- Pages
- 1924-1929
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2752935
- OpenAlex
- W2121535401
- Cited by
- 439
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 34 · 2018: 21 · 2017: 28 · 2016: 27 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60DK2054, P60DK020541)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin therapy, type 2 diabetes, incident diabetes risk, WOSCOPS, Heart Protection Study, ASCOT trial, JUPITER trial, CORONA trial, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

